Education
About Us
Working with TipRanks
Follow Us
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Top Page
Santhera Pharmaceuticals Holding
(SANN)
Select Model
Select Model
Rating:41Neutral
Price Target:
CHF10.00
▼(-4.94% Downside)
Santhera Pharmaceuticals' overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The positive sentiment from the earnings call provides some optimism, but the company's high leverage and ongoing losses weigh heavily on its valuation.
Positive Factors
Market Expansion
The expansion into new markets like the U.K. and Europe enhances Santhera's market reach and potential revenue streams, supporting long-term growth.
Product Adoption
Strong adoption of AGAMREE in key markets indicates robust demand and competitive positioning, which can drive sustained revenue growth.
Revenue Guidance
Increased revenue guidance reflects confidence in market performance and product demand, suggesting potential for improved financial results.
Negative Factors
High Leverage
High leverage indicates reliance on debt financing, which can strain financial flexibility and increase risk during economic downturns.
Operating Loss
Significant operating losses highlight ongoing profitability challenges, which may impact long-term financial sustainability if not addressed.
Cash Flow Challenges
Negative cash flow from operations suggests difficulties in self-financing, necessitating reliance on external funding, which could hinder growth.
Santhera Pharmaceuticals Holding (SANN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
$140.58M
Dividend YieldN/A
Average Volume (3M)95.23K
Price to Earnings (P/E)2.6
Beta (1Y)0.35
Revenue Growth-56.85%
EPS Growth-186.55%
CountryCH
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.04
Shares Outstanding14,010,270
10 Day Avg. Volume100,934
30 Day Avg. Volume95,230
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.68
Price to Sales (P/S)4.02
P/FCF Ratio-4.41
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit35.80
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
$30.00Price Target Upside185.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Santhera Pharmaceuticals Holding Business Overview & Revenue Model
Company DescriptionSanthera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
How the Company Makes MoneySanthera Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products. Key revenue streams include sales of approved drugs, potential royalties from partnered products, and milestone payments from collaborations with other pharmaceutical companies. The company actively seeks partnerships to expand its market reach and enhance its product pipeline. Additionally, Santhera may receive funding through grants and subsidies aimed at supporting research and development in rare diseases, which contribute to its financial sustainability.
Santhera Pharmaceuticals Holding Earnings Call Summary
Earnings Call Date:Sep 23, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.Q2-2025 Updates
Positive Updates
Strong AGAMREE Adoption in Key Markets
AGAMREE has achieved approximately 40% market share of steroid using DMD patients in Germany and Austria, with Austria exceeding 50% market share.
U.S. Market Performance
Catalyst reported H1 2025 sales of USD 49.4 million, on track to meet the full-year guidance of $100 million to $110 million, which would trigger a $12.5 million milestone payment to Santhera.
Successful Commercial Rollout in China
Sperogenix commenced non-reimbursed commercial rollout in China with over 250 patients, representing significant growth potential.
Increased Revenue Guidance
Santhera increased its revenue guidance for 2025, expecting revenues to exceed CHF 65 million to CHF 70 million due to strong market performances.
Negative Updates
Operating Loss
Santhera reported an operating loss of CHF 35.4 million for the first half of the year.
Additional Financing Required
The company secured an additional CHF 20 million in financing due to increased inventory needs and delayed cash flow breakeven.
Company Guidance
During the Santhera Pharmaceuticals half-year results call for the fiscal year 2025, Catherine Isted, the CFO, provided key financial guidance and metrics. The company announced new financing of CHF 20 million, extending their runway to cash flow breakeven by mid-2026. Santhera's cash balance was CHF 18.4 million as of June 30, 2025. The company's global sales reached over $100 million, and they expect full-year revenues to exceed CHF 65-70 million. Sales from their U.S. partner, Catalyst, were USD 49.4 million in H1 2025, with a full-year forecast of $100-110 million. This could trigger a $12.5 million milestone payment. Additionally, they anticipate strong growth in China following Sperogenix's commercial rollout, with over 250 patients already on AGAMREE. Santhera is expanding its market presence with recent launches in the U.K. and other European countries, aiming for a market size exceeding $600 million, including potential revenues from Europe, North America, and China as well as distribution agreements in other regions.Santhera Pharmaceuticals Holding Financial Statement Overview
Summary
Santhera Pharmaceuticals faces significant financial challenges, including volatile revenue, negative profitability, high leverage, and cash flow difficulties. The strong revenue year in 2023 offers some hope, but operational improvements are crucial for stability.Income Statement
Santhera Pharmaceuticals has shown a volatile revenue trend with a significant drop in 2024 compared to 2023. The company struggles with profitability as indicated by negative EBIT and net income margins. However, past revenue growth was notable in 2023, suggesting potential for recovery if operational issues are addressed.45
Neutral
Balance Sheet
The company's balance sheet shows high leverage with a debt-to-equity ratio exceeding 1, indicating reliance on debt financing. The equity ratio is low, reflecting weak equity position. Persistent negative stockholders' equity in some years raises concerns about financial stability.30
Negative
Cash Flow
Cash flow from operations has been negative in recent years, indicating challenges in generating cash internally. Positive financing cash flows highlight reliance on external funding. Free cash flow turned negative, suggesting cash management issues despite periods of positive operating cash flow in the past.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.02M | 39.12M | 103.41M | 7.47M | -1.59M | 15.01M |
| Gross Profit | 5.89M | 22.96M | 100.18M | 3.88M | -5.36M | 4.58M |
| EBITDA | -32.52M | -15.89M | 79.17M | -46.78M | -34.57M | -53.43M |
| Net Income | -65.54M | -41.97M | 54.78M | -71.08M | -55.53M | -67.66M |
Balance Sheet | ||||||
| Total Assets | 130.77M | 152.49M | 109.63M | 63.73M | 91.12M | 88.69M |
| Cash, Cash Equivalents and Short-Term Investments | 18.40M | 40.92M | 30.37M | 1.35M | 21.21M | 12.41M |
| Total Debt | 76.30M | 40.62M | 21.55M | 44.44M | 42.98M | 71.17M |
| Total Liabilities | 133.33M | 124.79M | 49.69M | 107.41M | 89.79M | 95.04M |
| Stockholders Equity | -2.56M | 27.70M | 59.94M | -43.69M | 1.33M | -6.35M |
Cash Flow | ||||||
| Free Cash Flow | -40.92M | -35.68M | 23.53M | -33.80M | -37.37M | -43.54M |
| Operating Cash Flow | -40.84M | -35.53M | 47.27M | -29.84M | -37.36M | -43.51M |
| Investing Cash Flow | -142.00K | -61.00K | -18.04M | -3.93M | 69.00K | 1.56M |
| Financing Cash Flow | 44.82M | 46.08M | -171.00K | 13.99M | 46.02M | 23.15M |
Santhera Pharmaceuticals Holding Technical Analysis
Negative
10.52
Price Trends
12.56
Negative
12.76
Negative
13.71
Negative
Market Momentum
-0.69
Negative
37.58
Neutral
81.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SANN, the sentiment is Negative. The current price of 10.52 is above the 20-day moving average (MA) of 10.40, below the 50-day MA of 12.56, and below the 200-day MA of 13.71, indicating a bearish trend. The MACD of -0.69 indicates Negative momentum. The RSI at 37.58 is Neutral, neither overbought nor oversold. The STOCH value of 81.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SANN.
Santhera Pharmaceuticals Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $267.88M | 11.20 | ― | ― | 744.64% | ― | |
68 Neutral | CHF586.49M | 8.05 | ― | ― | 58.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | CHF965.38M | ― | ― | ― | 67.18% | -480.10% | |
50 Neutral | $114.46M | ― | -48.90% | ― | -91.34% | -2.84% | |
41 Neutral | $140.58M | 2.58 | -301.13% | ― | -56.85% | -186.55% |
* Healthcare Sector Average
CH:SANN
Santhera Pharmaceuticals Holding
10.52
1.53
17.02%
CH:MOLN
Molecular Partners AG
2.75
-3.05
-52.59%
CH:BSLN
Basilea Pharmaceutica
48.65
4.25
9.57%
CH:IDIA
Idorsia Ltd
3.71
2.54
217.09%
CH:NWRN
Newron Pharmaceuticals SpA
14.34
5.34
59.33%
CH:XLS
Xlife Sciences Ltd.
20.80
-4.80
-18.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.